Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Pipeline Review, H2 2017 Summary According to the recently published report 'Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H2 2017'; Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function. The report 'Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H2 2017' outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 3 and 5 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Gastrointestinal, Dermatology, Metabolic Disorders, Respiratory and Women's Health which include indications Autoimmune Disorders, Breast Cancer, Allergies, Chronic Pain, Contact Dermatitis, Inflammatory Bowel Disease, Non-Small Cell Lung Cancer, Osteoarthritis Pain, Bladder Cancer, Cervical Cancer, Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Endometriosis, Epithelial Ovarian Cancer, Gastrointestinal Tract Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Inflammatory Pain, Lung Cancer, Osteoporosis, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Solid Tumor and Ulcerative Colitis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - The report reviews Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics and enlists all their major and minor projects - The report assesses Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents
2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Overview 6 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Development 7 Products under Development by Stage of Development 7 Products under Development by Therapy Area 8 Products under Development by Indication 9 Products under Development by Companies 12 Products under Development by Universities/Institutes 16 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Assessment 18 Assessment by Mechanism of Action 18 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Companies Involved in Therapeutics Development 24 Eisai Co Ltd 24 Eli Lilly and Company 25 Kaken Pharmaceutical Co Ltd 25 Ono Pharmaceutical Co Ltd 26 RaQualia Pharma Inc 26 Rottapharm Biotech Srl 27 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drug Profiles 28 AAT-008 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 CR-6086 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 E-7046 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 ER-886046 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 grapiprant - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 KAG-308 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 ONO-4578 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 P-001 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Small Molecule to Agonize EP4 Receptor for Osteoporosis - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Small Molecule to Antagonize EP4 Receptor for Inflammatory Pain - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Dormant Products 41 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Discontinued Products 42 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Product Development Milestones 43 Featured News & Press Releases 43 Jul 25, 2012: RaQualia Pharma Receives Allowance For EP4 Antagonist Substance Patent In Japan 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables
Number of Products under Development by Stage of Development, H2 2017 7 Number of Products under Development by Therapy Areas, H2 2017 8 Number of Products under Development by Indications, H2 2017 10 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 11 Number of Products under Development by Companies, H2 2017 12 Products under Development by Companies, H2 2017 13 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 15 Number of Products under Investigation by Universities/Institutes, H2 2017 16 Products under Investigation by Universities/Institutes, H2 2017 17 Number of Products by Stage and Mechanism of Actions, H2 2017 19 Number of Products by Stage and Route of Administration, H2 2017 21 Number of Products by Stage and Molecule Type, H2 2017 23 Pipeline by Eisai Co Ltd, H2 2017 24 Pipeline by Eli Lilly and Company, H2 2017 25 Pipeline by Kaken Pharmaceutical Co Ltd, H2 2017 25 Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 26 Pipeline by RaQualia Pharma Inc, H2 2017 26 Pipeline by Rottapharm Biotech Srl, H2 2017 27 Dormant Projects, H2 2017 41 Discontinued Products, H2 2017 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
